To date, incretin-based approaches for obesity management appear as the most promising and rapidly developing (Supplementary Table 1), with innovations such as once-weekly (OW) injectable triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), cagrilintide (long-acting amylin analogue)/semaglutide 2.4 mg (CagriSema) combination, GCGR/GLP-1R dual agonists, high-dose oral semaglutide, and oral non-peptide GLP-1 receptor agonist orforglipron, with relevant implications in terms of patients compliance and environmental sustainability
Storage conditions in the real world vary widely (temperature fluctuations, humidity, light exposure, shipping conditions)
It's on the WADA banned list, even though athletes get Toradol injections (known to have long-term risks) just to get back on the field
Misidentifying a line by one mark introduces a 2% volume error per injection, which compounds across a full protocol